Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177788168> ?p ?o ?g. }
- W3177788168 endingPage "1489" @default.
- W3177788168 startingPage "1470" @default.
- W3177788168 abstract "Aberrations in the PI3K/AKT/mTOR survival pathway in many cancers are the most common genomic abnormalities. The phytochemical and bioactive agent sulforaphane (SFN) has nutrigenomic potential in activating the expression of several cellular protective genes via the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2). Nrf2 is primarily related to mechanisms of endogenous cellular defense and survival. The efficacy of SFN in combination with acetazolamide (AZ) was investigated in reducing typical H727 and atypical H720 BC survival, migration potential, and apoptosis in vitro and in vivo preclinical xenograft tissues.Microscopic imaging, immunocytochemistry, wound healing assay, caspase-cleaved cytokeratin 18 (M30, CCK18) CytoDeath ELISA assay, immunofluorescence labeling assays for apoptosis, hypoxia, Western Blotting, Tunnel assay, measurement of 5-HT secretion by carbon fiber amperometry assay, quantitative methylation-specific PCR (qMSP), morphologic changes, cell viability, apoptosis activity and the expression levels of phospho-Akt1, Akt1, HIF-1α, PI3K, p21, CAIX, 5-HT, phospho-mTOR, and mTOR in xenografts derived from typical H727 and atypical H720 BC cell lines.Combining AZ+SFN reduced tumor cell survival compared to each agent alone, both in vitro and in vivo xenograft tissues. AZ+SFN targeted multiple pathways involved in cell cycle, serotonin secretion, survival, and growth pathways, highlighting its therapeutic approach. Both H727 and H720 cells were associated with induction of apoptosis, upregulation of the p21 cell cycle inhibitor, and downregulation of the PI3K/Akt/mTOR pathway, suggesting that the PI3K/Akt/mTOR pathway is a primary target of the AZ+SFN combination therapy.Combining SFN+AZ significantly inhibits the PI3K/Akt/mTOR pathway and significantly reducing 5-HT secretion in carcinoid syndrome." @default.
- W3177788168 created "2021-07-19" @default.
- W3177788168 creator A5005931876 @default.
- W3177788168 creator A5011760848 @default.
- W3177788168 creator A5021937638 @default.
- W3177788168 creator A5026699953 @default.
- W3177788168 creator A5036167539 @default.
- W3177788168 creator A5036881691 @default.
- W3177788168 creator A5043200158 @default.
- W3177788168 creator A5049914982 @default.
- W3177788168 creator A5053078335 @default.
- W3177788168 creator A5067117962 @default.
- W3177788168 creator A5086616644 @default.
- W3177788168 creator A5086700020 @default.
- W3177788168 date "2021-07-20" @default.
- W3177788168 modified "2023-10-17" @default.
- W3177788168 title "Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis" @default.
- W3177788168 cites W1480219105 @default.
- W3177788168 cites W1627803359 @default.
- W3177788168 cites W197322975 @default.
- W3177788168 cites W1982890673 @default.
- W3177788168 cites W2012762703 @default.
- W3177788168 cites W2014755770 @default.
- W3177788168 cites W2017657232 @default.
- W3177788168 cites W2056489198 @default.
- W3177788168 cites W2066241876 @default.
- W3177788168 cites W2078553155 @default.
- W3177788168 cites W2081764707 @default.
- W3177788168 cites W2085053724 @default.
- W3177788168 cites W2097772950 @default.
- W3177788168 cites W2098681351 @default.
- W3177788168 cites W2117462751 @default.
- W3177788168 cites W2118256381 @default.
- W3177788168 cites W2118793608 @default.
- W3177788168 cites W2122148781 @default.
- W3177788168 cites W2124084517 @default.
- W3177788168 cites W2130160735 @default.
- W3177788168 cites W2135991329 @default.
- W3177788168 cites W2137901835 @default.
- W3177788168 cites W2137959890 @default.
- W3177788168 cites W2138271341 @default.
- W3177788168 cites W2147163113 @default.
- W3177788168 cites W2152937132 @default.
- W3177788168 cites W2156387230 @default.
- W3177788168 cites W2161446823 @default.
- W3177788168 cites W2164916751 @default.
- W3177788168 cites W2169035402 @default.
- W3177788168 cites W2169385597 @default.
- W3177788168 cites W2171665032 @default.
- W3177788168 cites W2256291087 @default.
- W3177788168 cites W2272839087 @default.
- W3177788168 cites W2318785181 @default.
- W3177788168 cites W2324799017 @default.
- W3177788168 cites W2342911813 @default.
- W3177788168 cites W2432855159 @default.
- W3177788168 cites W2465286361 @default.
- W3177788168 cites W2504947281 @default.
- W3177788168 cites W2507289596 @default.
- W3177788168 cites W2509817044 @default.
- W3177788168 cites W2518718875 @default.
- W3177788168 cites W2519719294 @default.
- W3177788168 cites W2522884107 @default.
- W3177788168 cites W2534535431 @default.
- W3177788168 cites W2589064393 @default.
- W3177788168 cites W2591383443 @default.
- W3177788168 cites W2600452401 @default.
- W3177788168 cites W2610137909 @default.
- W3177788168 cites W2611475096 @default.
- W3177788168 cites W2737455129 @default.
- W3177788168 cites W2791008574 @default.
- W3177788168 cites W2791441440 @default.
- W3177788168 cites W2945113757 @default.
- W3177788168 cites W2966525921 @default.
- W3177788168 cites W2967026559 @default.
- W3177788168 cites W2971334346 @default.
- W3177788168 cites W2984955289 @default.
- W3177788168 cites W2995204555 @default.
- W3177788168 cites W3003807413 @default.
- W3177788168 cites W3089872715 @default.
- W3177788168 doi "https://doi.org/10.18632/oncotarget.28011" @default.
- W3177788168 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8310668" @default.
- W3177788168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34316328" @default.
- W3177788168 hasPublicationYear "2021" @default.
- W3177788168 type Work @default.
- W3177788168 sameAs 3177788168 @default.
- W3177788168 citedByCount "9" @default.
- W3177788168 countsByYear W31777881682021 @default.
- W3177788168 countsByYear W31777881682022 @default.
- W3177788168 countsByYear W31777881682023 @default.
- W3177788168 crossrefType "journal-article" @default.
- W3177788168 hasAuthorship W3177788168A5005931876 @default.
- W3177788168 hasAuthorship W3177788168A5011760848 @default.
- W3177788168 hasAuthorship W3177788168A5021937638 @default.
- W3177788168 hasAuthorship W3177788168A5026699953 @default.
- W3177788168 hasAuthorship W3177788168A5036167539 @default.
- W3177788168 hasAuthorship W3177788168A5036881691 @default.
- W3177788168 hasAuthorship W3177788168A5043200158 @default.
- W3177788168 hasAuthorship W3177788168A5049914982 @default.